Moderna Surges on Cancer Vaccine Breakthrough, Emerges as Market Darling
TL;DR
Moderna’s personalized mRNA cancer vaccine Intismeran Autogene, developed with Merck, showed Phase 3 melanoma trial success when paired with Keytruda, triggering a roughly 176% stock rally and making Moderna the S&P 500’s second-best performer this year as analysts boost bets on its cancer pipeline, though the magnitude of benefit and potential launches remain under review.
- Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough Yahoo Finance
- Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC
- Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines Financial Times
- Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss Bloomberg.com
- Moderna and Merck say melanoma vaccine succeeded in large trial CNN
Want the full story? Read the original reporting
Read on Yahoo Finance